Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Drug Profile

Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Alternative Names: CYC 800 series; CYC-140; CYC800; Plk1 inhibitors - Cyclacel; Polo-like kinase 1 inhibitors - Cyclacel; Research programme: cell cycle modulators - Cyclacel

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitosis inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours
  • No development reported Cancer

Most Recent Events

  • 04 Apr 2018 Preclinical trials in Haematological malignancies in USA (PO), prior to April 2018 (Cyclacel pipeline, April 2018)
  • 04 Apr 2018 Preclinical trials in Solid tumours in USA (PO), prior to April 2018 (Cyclacel pipeline, April 2018)
  • 28 Mar 2018 Cyclacel plans a first-in-human phase I trial for Cancer, in 2018 (Cyclacel pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top